Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead

Bristol stresses comprehensive approach to lung cancer – its top priority – with trials from early to late stages, a thoughtful biomarker development program and a pipeline stocked with drugs that have a wide range of targets.